Skip to main content

Table 4 Clinical and functional status at one-year follow-up by APR levels among biologic-naïve patients

From: Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

  Neither APR elevated APR levels discordant Both APR elevated P value
  n = 1,012 n = 487 n = 324  
mHAQ 0.28 ± 0.40 0.32 ± 0.43 0.34 ± 0.46 0.0623
CDAI 9.65 ± 10.11 9.75 ± 9.81 10.85 ± 11.17 0.2243
Tender joints 2.64 ± 4.93 2.41 ± 4.33 2.83 ± 5.17 0.4378*
Swollen joints 2.90 ± 4.66 2.91 ± 4.54 3.52 ± 5.04 0.1299*
Patient global assessment 26.23 ± 24.77 28.36 ± 25.62 28.68 ± 26.53 0.1149
MD global assessment 14.52 ± 14.82 15.61 ± 15.38 16.43 ± 15.85 <0.0001
Biologic use 150 (14.84%) 83 (17.08%) 67 (20.68%) 0.0437
  1. *Log-linear model (Poisson) - χ2 test. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.